

MIMETAS


Introduction of MIMETAS

Yoko Ejiri, President of Mimetas Japan KK

2025/10/16


Grow. Learn. Discover.

Models that Capture Human Physiology



MIMETAS provides **human-relevant disease models** that enable development of **more effective and safer therapies** by replicating patient disease processes


Based on proven technology, trusted team & large customer base



Why MIMETAS

1


Perfused vasculature



Perfused blood vessels and epithelial tubules

2


Comprehensive



Real tissues comprised of the crucial cell types

3

Quantification




Quantitative data from robust cultures

MIMETAS

4


No artificial membranes



Cells can migrate, interact and self-organize

5

Unmatched Throughput



Comprehensive, yet high throughput


Key Differentiators From Other Organoid solutions

Key Differentiators From Other Organ-on-a-Chip Solutions

Expertise across multiple organs...




Gut



- Adult stem cell derived organoids
- Co-culture with stroma and vasculature
- Tissue resident macrophages




Liver



- Primary hepatocytes
- Perfusable LSEC vascular plexus
- Stellate cells
- Perfused and resident immune cells




Lung



- Air lifted epithelium
- Perfused vasculature
- Fibroblasts
- Immune cell perfusion




Nervous system



- iPSC neurons
- Axonal outgrowth
- Astrocytes and microglia
- Perfused brain endothelium
- Inflammation




Kidney



- Adult stem cell derived tubuloids
- Proximal and distal phenotype
- Co-culture with vasculature and immune cells
- Glomerulus from primary isolated material
- Podocytes and glomerular endothelium

MIMETAS delivers value in all phases of drug discovery



Working with MIMETAS: a trusted partner for top pharma



- 50 highly skilled scientists in the lab;
- Working with top-20 pharmaceutical companies
- 10 years trusted relationships with world's globally leading pharmaceutical companies;
- 200 projects successfully executed covering all phases of drug discovery and development;

MIMETAS Contributes with Human Organ-on-Chip Data to IND Application by argenx

Leiden, July 11, 2024 - MIMETAS, a global leader in organ-on-chip-based disease models for drug discovery and development, announce an Investigational New Drug (IND) filing by argenx, supported by data from MIMETAS.

[Read more](#)



MIMETAS and Astellas Enter into Strategic Partnership on Immuno-oncology

Leiden, March 28, 2023 - MIMETAS, a global leader in human disease modeling announces that it has entered into a strategic partnership with Astellas Pharma Inc., a global pharmaceutical company.

[Read more](#)



MIMETAS Achieves Important Milestones in Partnership with Roche

Leiden, March 22, 2023 - MIMETAS has achieved major milestones in its partnership with Roche, developing models for Inflammatory Bowel Disease (IBD) and Hepatitis B Virus Infections (HBV).

[Read more](#)





Europe



Leiden Science Park, The Netherlands

- MIMETAS' headquarters
- R&D Hub & training facility
- Phenotypic Screening Center
- Commercial Ops

Enschede, The Netherlands

- OrganoPlate Production
- Logistics

USA



Gaithersburg, MD, United States

- R&D projects
- Training
- Commercial Ops

Asia



Tokyo, Japan

- Commercial Ops
- Distribution

The logo for MIMETAS, featuring the word in a stylized, blocky font with a green-to-yellow gradient. The background of the slide is a complex, colorful network of glowing lines in shades of blue, green, and orange, resembling a neural network or a biological structure.

MIMETAS

Contact us: info-jp@mimetas.com

Grow. Learn. Discover.